Raymond Dittamore Net Worth

The estimated Net Worth of Raymond V Dittamore is at least $1.52 Milion dollars as of 30 September 2016. Mr. Dittamore owns over 18,000 units of Obalon Therapeutics Inc stock worth over $11,080 and over the last 20 years he sold OBLN stock worth over $1,507,060. In addition, he makes $0 as Independent Director at Obalon Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Dittamore OBLN stock SEC Form 4 insiders trading

Raymond has made over 18 trades of the Obalon Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 18,000 units of OBLN stock worth $1,231,020 on 30 September 2016.

The largest trade he's ever made was exercising 20,000 units of Obalon Therapeutics Inc stock on 20 November 2013 worth over $627,600. On average, Raymond trades about 4,328 units every 90 days since 2004. As of 30 September 2016 he still owns at least 4,000 units of Obalon Therapeutics Inc stock.

You can see the complete history of Mr. Dittamore stock trades at the bottom of the page.

Raymond Dittamore biography

Raymond V. Dittamore is Independent Director of the company since March 2016. Mr. Dittamore retired in June 2001 as a partner of Ernst & Young LLP, an international public accounting firm, after 35 years of service. Mr. Dittamore currently serves on the board of directors of QUALCOMM Incorporated, a semiconductor and telecommunications equipment company. Mr. Dittamore previously served on the boards of directors of Life Technologies Corporation, Gen-Probe Incorporation and Digirad Corporation. Mr. Dittamore holds a B.S. degree in accounting from San Diego State University. Our board of directors believes that Mr. Dittamore’s extensive auditing and accounting experience as well as his industry knowledge qualifies him to serve on our board of directors.

How old is Raymond Dittamore?

Raymond Dittamore is 73, he's been the Independent Director of Obalon Therapeutics Inc since 2016. There are no older and 12 younger executives at Obalon Therapeutics Inc.

What's Raymond Dittamore's mailing address?

Raymond's mailing address filed with the SEC is C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD, CA, 92008.

Insiders trading at Obalon Therapeutics Inc

Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma... a David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.

What does Obalon Therapeutics Inc do?

Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

Complete history of Mr. Dittamore stock trades at Atyr Pharma Inc, Digirad Corp, Obalon Therapeutics Inc a Qualcomm

Obalon Therapeutics Inc executives and stock owners

Obalon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Kelly Huang Ph.D.,
  Consultant
• Andrew Rasdal,
  Chairman of the Board, President, Chief Executive Officer
• Andrew P. Rasdal,
  CEO, Pres & Director
• Sharon Stevenson,
  Independent Director
• Lesley Howe,
  Independent Director
• Douglas Fisher,
  Independent Director
• Raymond Dittamore,
  Independent Director
• William Plovanic,
  Director
• Robert MacDonald,
  Chief Retail Officer
• Donald Young,
  Vice President of Quality Assurance
• Todd Wood,
  Vice President - Global Sales
• Lisa Metzner,
  Vice President of Marketing
• Matthew Norwood,
  Vice President of Sales
• Steve Johnson,
  Vice President - Operations
• Nooshin Hussainy,
  Chief Financial Officer
• Nooshin Hussainy,
  CFO & Sec.
• Kim P. Kamdar,
  
• Erin Morisey,
  VP Strategic Partnerships
• Partners X Lp Inter West Ma...,
  
• David Moatazedi,
  
• Vii Associates Lpblair Jame...,
  
• Parters Vii L Pblair James ...,
  
• Amy Vanden Berg,
  Chief Clinical & Reg Officer
• Kelly Huang,
  Pres & Chief Executive Officer
• Robert H Jr Mondore,
  VP of Operations
• Jonah Shacknai,
  
• Partners X Lp Inter West Ma...,
  
• Daina Schmidt,
  Vice President of Marketing
• Mark Brister,
  Chief Technology Officer